gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PRLDHealthcarePharmaceuticals

Prelude Therapeutics Incorporated (PRLD)

$4.08+7.94%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$3.78▼ 5.03% in range
Nov 3, 2025Low $1.19 · High $6.63Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Prelude Therapeutics Incorporated closed at $4.08 on Nov 4, up 7.94%, 38.5% below its 52-week closing high. Volume of 378.0K shares was 0.90× its 20-day average (close to normal).

Split-adjusted performance: +7.1% over one month, -15.7% over six months, +2.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $5.70M, with a net margin of -244.1%.

Short interest was 5.1M shares at the Oct 15 settlement, up 11.4% from the prior report (13.2% of float, 11.5 days to cover).

Market cap$325.6M79.8M shares
Revenue · quarter$5.7M—
Diluted EPS$-0.14—
P/E · TTM—P/S 14.5×
Net margin-244.1%Gross 100.0%
Dividend yieldNone
52-week range1.19 – 6.63−38.5% from high
Volume378.0K0.90× 20-day avg
Volatility · 60d73.7%Annualised
Short % of float13.2%11.5 days to cover
Net cash$151.8MCash $151.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −1.4%1M +7.1%3M −12.8%6M −15.7%YTD +40.7%1Y +2.5%3Y +127.9%5Y −76.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum60
Revenue growth—
Net margin34
Value (low P/E)—
Size55

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short5.1M+11.4% vs prior
Days to cover11.5Settled Oct 15
% of float13.2%
Short vol. 10d55.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PRLDPrelude Therapeutics Incorporated$4.08+7.94%−15.7%—−244.1%—$325.6M
BNTCBenitec Biopharma$9.28+10.48%−26.2%———$323.8MCompare
CGCCanopy Growth$0.7517+6.37%−34.6%+7.8%−18.0%—$318.0MCompare
ENTAEnanta Pharmaceuticals$10.65+2.70%−30.1%−21.6%−135.8%—$310.2MCompare
CYPHCypherpunk Technologies$2.87+10.38%+154.0%———$309.3MCompare
ARCTArcturus Therapeutics Holdings$10.87+13.94%+19.1%−89.5%−803.8%—$309.0MCompare
SPRYARS Pharmaceuticals$3.050.00%−67.1%+114.2%−185.2%—$303.3MCompare
GALTGalectin Therapeutics$3.47+3.58%+54.2%———$349.9MCompare
EBSEmergent Biosolutions$5.90−5.60%−35.2%−52.4%−29.7%—$302.5MCompare

News about Prelude Therapeutics Incorporated

All news →
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026GlobeNewswire Inc. · Apr 20, 2026▲ Positive

Quick answers

What does Prelude Therapeutics Incorporated do?
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients.
What is PRLD's market cap?
$325.60M, based on the Nov 4 close of $4.08.
Does Prelude Therapeutics Incorporated pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PRLD is sold short?
5.1M shares, 13.2% of float, as of Oct 15, 2026.
What sector is PRLD in?
Healthcare, in the Pharmaceuticals industry.

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

HQ: Wilmington, DE79 employeesListed Sep 25, 2020preludetx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology